scholarly journals Response to the letter: Angiotensin-II induced insulin resistance

2014 ◽  
Vol 58 (9) ◽  
pp. 972-973
Author(s):  
Marcos M. Lima-Martínez ◽  
Gabriel López-Mendez ◽  
Rodolfo Odreman ◽  
José H. Donis ◽  
Mariela Paoli
1999 ◽  
Vol 277 (5) ◽  
pp. E920-E926 ◽  
Author(s):  
Joyce M. Richey ◽  
Marilyn Ader ◽  
Donna Moore ◽  
Richard N. Bergman

We set out to examine whether angiotensin-driven hypertension can alter insulin action and whether these changes are reflected as changes in interstitial insulin (the signal to which insulin-sensitive cells respond to increase glucose uptake). To this end, we measured hemodynamic parameters, glucose turnover, and insulin dynamics in both plasma and interstitial fluid (lymph) during hyperinsulinemic euglycemic clamps in anesthetized dogs, with or without simultaneous infusions of angiotensin II (ANG II). Hyperinsulinemia per se failed to alter mean arterial pressure, heart rate, or femoral blood flow. ANG II infusion resulted in increased mean arterial pressure (68 ± 16 to 94 ± 14 mmHg, P < 0.001) with a compensatory decrease in heart rate (110 ± 7 vs. 86 ± 4 mmHg, P < 0.05). Peripheral resistance was significantly increased by ANG II from 0.434 to 0.507 mmHg ⋅ ml−1⋅ min ( P < 0.05). ANG II infusion increased femoral artery blood flow (176 ± 4 to 187 ± 5 ml/min, P < 0.05) and resulted in additional increases in both plasma and lymph insulin (93 ± 20 to 122 ± 13 μU/ml and 30 ± 4 to 45 ± 8 μU/ml, P < 0.05). However, glucose uptake was not significantly altered and actually had a tendency to be lower (5.9 ± 1.2 vs. 5.4 ± 0.7 mg ⋅ kg−1⋅ min−1, P > 0.10). Mimicking of the ANG II-induced hyperinsulinemia resulted in an additional increase in glucose uptake. These data imply that ANG II induces insulin resistance by an effect independent of a reduction in interstitial insulin.


2009 ◽  
Vol 302 (2) ◽  
pp. 128-139 ◽  
Author(s):  
J. Alberto Olivares-Reyes ◽  
Araceli Arellano-Plancarte ◽  
J. Ramon Castillo-Hernandez

Metabolism ◽  
2004 ◽  
Vol 53 (6) ◽  
pp. 777-781 ◽  
Author(s):  
Futoshi Anan ◽  
Naohiko Takahashi ◽  
Tatsuhiko Ooie ◽  
Masahide Hara ◽  
Hironobu Yoshimatsu ◽  
...  

Endocrinology ◽  
2004 ◽  
Vol 145 (8) ◽  
pp. 3647-3651 ◽  
Author(s):  
Guangqun Xing ◽  
Tatsuo Shimosawa ◽  
Takehide Ogihara ◽  
Hiromitsu Matsui ◽  
Kanami Itakura ◽  
...  

2007 ◽  
Vol 293 (4) ◽  
pp. H2537-H2542 ◽  
Author(s):  
David W. Stepp ◽  
Erika I. Boesen ◽  
Jennifer C. Sullivan ◽  
James D. Mintz ◽  
Clark D. Hair ◽  
...  

Obesity is an emerging risk factor for renal dysfunction, but the mechanisms are poorly understood. Obese patients show heightened renal vasodilation to blockade of the renin-angiotensin system, suggesting deficits in vascular responses to angiotensin II (ANG II). This study tested the hypothesis that obesity augments renal vasoconstriction to ANG II. Lean (LZR), prediabetic obese (OZR), and nonobese fructose-fed Zucker rats (FF-LZR) were studied to determine the effects of obesity and insulin resistance on reactivity of blood pressure and renal blood flow to vasoconstrictors. OZR showed enlargement of the kidneys, elevated urine output, increased sodium intake, and decreased plasma renin activity (PRA) vs. LZR, and renal vasoconstriction to ANG II was augmented in OZR. Renal reactivity to norepinephrine and mesenteric vascular reactivity to ANG II were similar between LZR and OZR. Insulin-resistant FF-LZR had normal reactivity to ANG II, indicating the insulin resistance was an unlikely explanation for the changes observed in OZR. Four weeks on a low-sodium diet (0.08%) to raise PRA reduced reactivity to ANG II in OZR back to normal levels without effect on LZR. From these data, we conclude that in the prediabetic stages of obesity, a decrease in PRA is observed in Zucker rats that may lead to increased renal vascular reactivity to ANG II. This increased reactivity to ANG II may explain the elevated renal vasodilator effects observed in obese humans and provide insight into early changes in renal function that predispose to nephropathy in later stages of the disease.


Hypertension ◽  
2001 ◽  
Vol 38 (4) ◽  
pp. 884-890 ◽  
Author(s):  
Erik J. Henriksen ◽  
Stephan Jacob ◽  
Tyson R. Kinnick ◽  
Mary K. Teachey ◽  
Michael Krekler

Sign in / Sign up

Export Citation Format

Share Document